Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

9(90.0%)

Phase 3

1(10.0%)

10Total

Phase 1(9)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT05039177Phase 1Completed

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Role: lead

NCT04670679Phase 1Active Not Recruiting

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Role: lead

NCT06346067Phase 3Active Not Recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Role: lead

NCT05907304Phase 1Active Not Recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Role: lead

NCT07021898Phase 1Recruiting

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

Role: lead

NCT06983743Phase 1Recruiting

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Role: lead

NCT05222802Phase 1Active Not Recruiting

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Role: collaborator

NCT04866134Phase 1Active Not Recruiting

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Role: lead

NCT04959981Phase 1Completed

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Role: lead

NCT05279859Phase 1Withdrawn

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Role: lead

All 10 trials loaded